Mersana Therapeutics Inc (MRSN.OQ)
MRSN.OQ on NASDAQ Stock Exchange Global Select Market
12.91USD
14 Aug 2018
12.91USD
14 Aug 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$12.91
$12.91
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
44,310
44,310
52-wk High
$23.67
$23.67
52-wk Low
$8.76
$8.76
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 3.06 | -0.544 |
| FY 2017 | Dec '17 | 3.26 | -0.613 |
| Sep '17 | 6.27 | -0.340 | |
| Jun '17 | 3.73 | -0.394 | |
| Mar '17 | 4.29 | -0.356 | |
| FY 2016 | Dec '16 | 12.00 | 0.056 |
| Sep '16 | 3.26 | -0.258 | |
| Jun '16 | 6.22 | -0.166 | |
| Mar '16 | 3.70 | -0.237 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 6 | 4.12 | 5.50 | 3.00 | 7.50 |
| Quarter Ending Dec-18 | 6 | 4.32 | 6.24 | 3.00 | 7.50 |
| Year Ending Dec-18 | 6 | 15.35 | 19.30 | 12.00 | 22.22 |
| Year Ending Dec-19 | 6 | 20.50 | 27.00 | 13.90 | 30.47 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 6 | -0.60 | -0.48 | -0.68 | -0.43 |
| Quarter Ending Dec-18 | 6 | -0.63 | -0.50 | -0.76 | -0.57 |
| Year Ending Dec-18 | 6 | -2.34 | -2.05 | -2.58 | -2.11 |
| Year Ending Dec-19 | 6 | -2.16 | -1.71 | -2.55 | -1.93 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 85.68 | 32.76 | |
| P/E High - Last 5 Yrs. | -- | 300.64 | 45.44 | |
| P/E Low - Last 5 Yrs. | -- | 92.08 | 24.26 | |
| Beta | -- | 0.93 | 0.89 | |
| Price to Sales (TTM) | -- | 114.98 | 5.75 | |
| Price to Book (MRQ) | -- | 15.51 | 5.47 | |
| Price to Tangible Book (MRQ) | 18.86 | 14.52 | 7.04 | |
| Price to Cash Flow (TTM) | -- | 72.88 | 23.29 | |
| % Owned Institutions | 78.13 | 14.70 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.36 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 1.72 | 5.22 | |
| Payout Ratio(TTM) | -- | 16.50 | 43.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 411.54 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 80.50 | 5.64 | |
| Sales - 5 Yr. Growth Rate | -- | 32.27 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -- | 29.15 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.84 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 40.43 | 15.34 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.91 | 2.22 |
| Current Ratio (MRQ) | 2.53 | 5.53 | 3.03 |
| LT Debt to Equity (MRQ) | 0.00 | 35.26 | 12.51 |
| Total Debt to Equity (MRQ) | 0.00 | 37.08 | 16.85 |
| Interest Coverage (TTM) | -- | -102.44 | 32.63 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 39.17 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.57 | 52.17 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -603.21 | 10.65 | |
| Operating Margin (TTM) | -- | -759.76 | 4.32 | |
| Operating Margin - 5 Yr. Avg. | -- | -625.13 | 6.06 | |
| Pre-Tax Margin (TTM) | -- | -733.60 | 5.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -628.46 | 6.49 | |
| Net Profit Margin (TTM) | -- | -734.98 | 1.48 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -631.51 | 2.77 | |
| Effective Tax Rate (TTM) | -- | 23.33 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.66 | 23.97 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 23,229,989 | 860,364,356 | |
| Net Income/Employee (TTM) | -- | 3,144,143 | 101,205,920 | |
| Receivable Turnover (TTM) | -- | 20.89 | 5.87 | |
| Inventory Turnover (TTM) | -- | 2.46 | 3.41 | |
| Asset Turnover (TTM) | -- | 0.41 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -- | -0.16 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | -- | 3.50 | 12.40 | |
| Return on Investment (TTM) | -- | 1.78 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | -- | 2.55 | 16.13 | |
| Return on Equity (TTM) | -- | 3.28 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | -- | 3.42 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 142.99 | -- | -- |
| EPS (TTM) % | 16.61 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Mersana Therapeutics Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 6.92 | 3.23 | 64 | 53 |
| 13 Week | 42.40 | 35.47 | 85 | 66 |
| 26 Week | -- | -- | -- | 80 |
| 52 Week | -- | -- | -- | 50 |
| YTD | -- | -- | -- | 61 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 1-Mersana's cancer drug trial put on hold by FDA; shares halted
- Mersana Therapeutics cancer drug trial on partial hold by FDA
- BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61
- BRIEF-Mersana Strengthens Board Of Directors Leadership With Appointment Of Willard H. Dere, M.D
- BRIEF-Mersana Therapeutics Increased Size Of Board From 7 To 8 Directors
Institutional Holders
| % Shares Owned: | 82.65% |
| # of Holders: | 90 |
| Total Shares Held: | 18,927,734 |
| 3 Mo. Net Change: | 46,557 |
| # New Positions: | 10 |
| # Closed Positions: | 8 |
| # Increased Positions: | 25 |
| # Reduced Positions: | 19 |
| # Net Buyers: | 6 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.